Interleukin-5 in the Pathophysiology of Severe Asthma.
Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. · 2019
Read Interleukin-5 in the Pathophysiology of Severe Asthma. by Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6927944.txt.
Description
Pelaia and co-authors review interleukin-5 in severe asthma. Their review appeared in Frontiers in Physiology. Interleukin-5, or IL-5, drives eosinophil biology. It shapes their growth, recruitment, survival, and degranulation. Those cells fuel eosinophilic airway inflammation.
Recent work has clarified how IL-5 acts. It builds, sustains, and amplifies the inflammatory response. That central role makes it a prime drug target. Some therapies block IL-5 itself. Mepolizumab and reslizumab work that way. Benralizumab instead blocks its receptor. These biologics can help patients with severe T2-high asthma. Such asthma often resists inhaled and systemic steroids. The review weighs the gains for that group.
Catalog record
| CREATOR | Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |